Clinical trials: Mild Cognitive Impairment
- Condition Mild Cognitive Impairment
- Funder type Industry (pharma, biotech, devices)
- Has posted results yes
Alzheimer Disease, Mild Cognitive Impairment
Evaluation of Web-based Training to Educate Physicians in the Methods of Interpreting Florbetapir-PET Scans
This study will investigate the performance of physician readers trained to read florbetapir-PET scans using electronic media training.
- Conditions
- Alzheimer Disease, Mild Cognitive Impairment, Neurodegenerative Diseases
- Trial name
- NCT01550549
- Testing
- florbetapir F 18
- Volunteers
- 151 people, healthy volunteers welcome
- Sponsor
- Avid Radiopharmaceuticals
Mild Cognitive Impairment, Alzheimer Disease
Safety and Immunogenicity of Repeated Doses of ABvac40 in Patients With a-MCI or Vm-AD
Alzheimer's disease (AD) is the most common type of dementia, accounting for 50-75% of the estimated 47 million people with dementia worldwide.
- Trial name
- NCT03461276
- Testing
- ABvac40
- Where
- 23 sites in France, Italy and 2 more
- Volunteers
- 134 people
- Sponsor
- Araclon Biotech S.L.
Alzheimer Disease, Cognitive Impairment
Safety, Efficacy and Dose Titration of Sodium Oligo-mannurarate Capsule on Mild to Moderate Alzheimer's Disease
The primary purpose of this study is to determine whether sodium oligo-mannurarate capsule is effective and safe in the treatment of mild to moderate alzheimer' disease, and to determine the best therapeutic dose of sodium…
- Trial name
- NCT01453569
- Testing
- Sodium oligo-mannurarate 600mg, Sodium oligo-mannurarate 900mg
- Where
- 24 sites in China
- Volunteers
- 255 people
- Sponsor
- Shanghai Greenvalley Pharmaceutical Co., Ltd.
Mild Cognitive Impairment, Dementia
A 3 Year Study to Evaluate the Safety and Efficacy of Low Dose Ladostigil in Patients With Mild Cognitive Impairment
The purpose of this study is to determine whether treatment with the investigational drug ladostigil will delay the onset of Alzheimer's disease(AD) in patients with Mild Cognitive Impairment (MCI).
- Trial name
- NCT01429623
- Testing
- ladostigil hemitartrate
- Where
- 12 sites in Austria, Germany and 1 more
- Volunteers
- 210 people
- Sponsor
- Avraham Pharmaceuticals Ltd
Mild Cognitive Impairment, Lewy Body Dementia, Parkinson's Disease Rapid Eye Movement Sleep Behavior Disorder, Parkinson's Disease Dementia
A Study of Clenbuterol (CST-103) Co-administered With Nadolol (CST-107) in Subjects With Neurodegenerative Disorders
This is a Phase II, randomized, placebo-controlled, double-blind, crossover study on the CNS and pharmacodynamic effects of clenbuterol (CST-103) co-administered with nadolol (CST-107) in 4 subject populations with…
- Trial name
- CLIN-011 (NCT04739423)
- Where
- 7 sites in Australia, New Zealand and 1 more
- Volunteers
- 41 people
- Sponsor
- CuraSen Therapeutics, Inc.
Alzheimer Disease, Dementia
A Study of XPro1595 in Patients With Early Alzheimer's Disease With Biomarkers of Inflammation
The goal of this Phase 2 Alzheimer's study is to determine whether 1.0 mg/kg XPro1595 confers a benefit on cognition, function, and biomarkers of white matter and to further evaluate safety and tolerability.
- Conditions
- Alzheimer Disease, Dementia, Brain Diseases, Central Nervous System Diseases
- Trial name
- MINDFuL (NCT05318976)
- Testing
- XPro1595
- Where
- 41 sites in Australia, Canada and 6 more
- Volunteers
- 207 people
- Sponsor
- Inmune Bio, Inc.
Mild Cognitive Impairment, Mild Dementia
A Study to Evaluate the Effects of SAGE-718 in Participants With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease (AD)
The primary purpose of this study is to evaluate the effect of SAGE-718 on cognitive performance in participants with Alzheimer's Disease.
- Conditions
- Mild Cognitive Impairment, Mild Dementia, Alzheimer's Disease
- Trial name
- NCT05619692
- Testing
- SAGE-718
- Where
- 39 sites in United States, Puerto Rico
- Volunteers
- 174 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
Alzheimer's Disease
Acute Effects Of Donepezil On Brain Perfusion And Memory In Subjects With Cognitive Impairment And Mild Alzheimer's Disease
The study hypothesizes that donepezil will have a positive impact on brain blood flow deficits in subjects with memory deficits and/or mild dementia and that improvements in brain blood flow will be accompanied by improvements in…
- Trial name
- NCT01082965
- Testing
- Donepezil
- Where
- 8 sites in United States
- Volunteers
- 18 people
- Sponsor
- Pfizer
Mild Cognitive Impairment Due to Alzheimer's Disease
Biomarker Qualification for Risk of Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease (AD) and Safety and Efficacy Evaluation of Pioglitazone in Delaying Its Onset
The purpose of this study is to qualify the biomarker risk algorithm for prognosis of the risk of developing Mild Cognitive Impairment due to Alzheimer's Disease (MCI-AD), and also to evaluate the efficacy of pioglitazone…
- Trial name
- TOMMORROW (NCT01931566)
- Testing
- Pioglitazone
- Where
- 55 sites in United States, Australia and 3 more
- Volunteers
- 3,494 people, healthy volunteers welcome
- Sponsor
- Takeda
Mild Cognitive Impairment, Alzheimer's Disease
Comparison of PET Amyloid Imaging in Japanese and Western Subjects
This was a Phase 2, multicenter study to assess the extent and patterns of [18F] flutemetamol uptake in the brains of 3 groups of Japanese subjects: healthy volunteers (HV), amnestic mild cognitive impairment (aMCI), and probable…
- Conditions
- Mild Cognitive Impairment, Alzheimer's Disease, Healthy
- Trial name
- NCT02813070
- Testing
- [18F] Flutemetamol
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- GE Healthcare
Healthy, Alzheimer's Disease
A Study of LY2599666 in Healthy Participants and Participants With Mild Cognitive Impairment or Alzheimer's Disease (AD)
The main purpose of this study is to evaluate the safety and tolerability of the study drug known as LY2599666 in different groups of people - those who are healthy, those who have mild cognitive impairment due to Alzheimer's…
- Conditions
- Healthy, Alzheimer's Disease, Mild Cognitive Impairment
- Trial name
- NCT02614131
- Testing
- LY2599666, Solanezumab
- Where
- 5 sites in United States, Japan
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Alzheimer's Disease
[18F]MK-3328 as a Possible Novel Positron Emission Tomography (PET) Tracer for the Detection of Brain Amyloid Plaques (MK-3328-002)
The purpose of this study is to evaluate radiolabeled [18F]MK-3328 as a PET tracer for estimating the regional distribution and extent of amyloid plaques in participants suffering from amnestic mild cognitive impairment (aMCI)…
- Trial name
- NCT01385033
- Testing
- [18F]MK-3328
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Mild Cognitive Impairment, Alzheimer Disease
Study of the Efficacy and Safety of Various Anti-inflammatory Agents in Participants With Mild Cognitive Impairment or Mild Alzheimer's Disease
The purpose of this platform study was to evaluate the effect of anti-inflammatory agents on cognition in early Alzheimer's disease.
- Trial name
- NCT04795466
- Testing
- Canakinumab
- Where
- 10 sites in United States, Finland and 2 more
- Volunteers
- 34 people
- Sponsor
- Novartis Pharmaceuticals
Alzheimer Disease
Comparative Efficacy, Safety, and Tolerability of Rivastigmine 10 and 15 cm^2 Patch in Patients With Alzheimer's Disease (AD) Showing Cognitive Decline
The purpose of this study was to support the optimal use of rivastigmine patch in long-term treatment of Alzheimer's Disease in patients demonstrating functional and cognitive decline at the target maintenance dose of…
- Trial name
- NCT00506415
- Testing
- Rivastigmine 5 cm^2, Rivastigmine 10 cm^2, Rivastigmine 15 cm^2
- Where
- 145 sites in United States, Canada and 5 more
- Volunteers
- 1,584 people
- Sponsor
- Novartis Pharmaceuticals
Mild Cognitive Impairment, Cognitive Decline
Effects of Walkasins on Gait Speed of Individuals With Mild Cognitive Impairments
The primary aim of this pilot study is to investigate the effect of Walkasins, a wearable lower-limb sensory prosthesis, on the gait speed and balance function of participants with mild cognitive impairment as measured by the…
- Conditions
- Mild Cognitive Impairment, Cognitive Decline, Gait Disorders in Old Age
- Trial name
- NCT05723822
- Testing
- Walkasins
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- RxFunction Inc.
Alzheimer's Disease
Evaluation of Safety & Tolerability of Multiple Dose Regimens of CHF 5074
To evaluate the safety and tolerability of ascending oral doses of CHF 5074 administered once per day for up to 12 weeks to patients with mild cognitive impairment.
- Trial name
- CT04 (NCT01303744)
- Testing
- CHF 5074 1x, CHF 5074 2x, CHF 5074 3x
- Where
- 9 sites in United States, Italy
- Volunteers
- 96 people
- Sponsor
- CERESPIR
Engagement, Patient, Mood
SimpleC Wellness Platform With Social Robot Interaction
This implementation study will be conducted to test a Socially-Assistive Robot (SAR) system for residents in an Assisted Living environment. The goal of the SAR system is to enhance social engagement and connectedness.
- Conditions
- Engagement, Patient, Mood, Quality of Life, Aging
- Trial name
- NCT05296239
- Testing
- SimpleC Wellness Platform with Social Robot Interaction
- Where
- 2 sites in United States
- Volunteers
- 26 people
- Sponsor
- SimpleC, LLC
Alzheimer's Disease
Evaluation of Inter-reader Reliability Using Images From Subjects With Alzheimer's Disease (AD) or Mild Cognitive Impairment (MCI)
Re-read of brain amyloid scans acquired in previous AV-45 clinical studies by readers trained using updated reading methodology.
- Trial name
- NCT01565382
- Testing
- florbetapir F 18
- Volunteers
- 40 people
- Sponsor
- Avid Radiopharmaceuticals
Dementia, Alzheimer Type
A Phase II Study to Assess the Safety, Tolerability and Efficacy of Xanamem™ in Subjects With Mild Dementia Due to AD (XanADu)
This XanADu Phase II study in mild Alzheimer's Disease (AD) is to assess the safety, tolerability and efficacy of Xanamem in subjects with mild dementia due to Alzheimer's Disease.
- Trial name
- XanADu (NCT02727699)
- Testing
- Xanamem™
- Where
- 25 sites in United States, Australia and 1 more
- Volunteers
- 185 people
- Sponsor
- Actinogen Medical
Alzheimer Disease
A Trial to Evaluate the Efficacy and Safety of PQ912 in Patients With Early AD
This is a Phase 2A multi-center, randomized, double blind, placebo-controlled, parallel group study of varoglutamstat, with a stage gate to Phase 2B.
- Trial name
- VIVA-MIND (NCT03919162)
- Testing
- PQ912
- Where
- 22 sites in United States
- Volunteers
- 112 people
- Sponsor
- Vivoryon Therapeutics N.V.